Dedicator of cytokinesis 8 (DOCK8) mutation impairs the differentiation of helper T cells by regulating the glycolytic pathway of CD4⁺ T cells

Abstract

Dedicator of cytokinesis 8 (DOCK8) deficiency is a primary immunodeficiency disease caused by mutations in exon 45 of the DOCK8 gene. The clinical signs primarily consist of increased serum IgE levels, eczema, repeated skin infections, allergies, and upper respiratory tract infections. Using CRISPR/Cas9 technology, we generated a DOCK8 exon 45 mutation in mice, mirroring the mutation found in patients. The results indicated that DOCK8 mutation impairs peripheral T cell homeostasis, disrupts regulatory T cells (Tregs) development, increases ICOS expression in Tregs within peripheral lymph nodes (pLn), and promotes Th17 cell differentiation within the spleen and pLn. Upon virus infection, DOCK8 mutation CD4⁺ T cells have a Th2 effector fate. RNA-bulk sequencing data revealed alternations in the mTOR pathway of DOCK8 mutant CD4⁺ T cells. We observed that DOCK8 mutation upregulates the glycolysis levels in CD4⁺ T cells, which is related to the Akt/mTOR/S6/HIF-1α pathway. In summary, our research elucidates that DOCK8 regulates the differentiation of helper T cells by modulating the glycolytic pathway in CD4⁺ T cells, thereby advancing the comprehension and offering potential treatment of diseases in DOCK8-deficient patients.

Keywords

differentiation / DOCK8 / glycolytic / T cell

References

[1] Gadea G, Blangy A. Dock-family exchange factors in cell migration and disease. Eur J Cell Biol. 2014; 93(10-12): 466-477.

[2] Ruusala A, Aspenström P. Isolation and characterisation of DOCK8, a member of the DOCK180-related regulators of cell morphology. FEBS Lett. 2004; 572(1-3): 159-166.

[3] Su HC. Dedicator of cytokinesis 8 (DOCK8) deficiency. Curr Opin Allergy Clin Immunol. 2010; 10(6): 515-520.

[4] Hall A. Rho family GTPases. Biochem Soc Trans. 2012; 40(6): 1378-1382.

[5] Laurin M, Côté JF. Insights into the biological functions of Dock family guanine nucleotide exchange factors. Genes Dev. 2014; 28(6): 533-547.

[6] Namekata K, Kimura A, Kawamura K, Harada C, Harada T. Dock GEFs and their therapeutic potential: Neuroprotection and axon regeneration. Prog Retin Eye Res. 2014; 43: 1-16.

[7] Randall KL, Lambe T, Johnson AL, et al. Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat Immunol. 2009; 10(12): 1283-1291.

[8] Randall KL, Chan SSY, Ma CS, et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med. 2011; 208(11): 2305-2320.

[9] Crawford G, Enders A, Gileadi U, et al. DOCK8 is critical for the survival and function of NKT cells. Blood. 2013; 122(12): 2052-2061.

[10] Zhang Q, Dove CG, Hor JL, et al. DOCK8 regulates lymphocyte shape integrity for skin antiviral immunity. J Exp Med. 2014; 211(13): 2549-2566.

[11] Yamamura K, Uruno T, Shiraishi A, et al. The transcription factor EPAS1 links DOCK8 deficiency to atopic skin inflammation via IL-31 induction. Nat Commun. 2017; 8: 13946.

[12] Engelhardt KR, McGhee S, Winkler S, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol. 2009; 124(6): 1289-1302. e4.

[13] Zhang Q, Jing H, Su HC. Recent advances in DOCK8 immunodeficiency syndrome. J Clin Immunol. 2016; 36(5): 441-449.

[14] Engelhardt KR, Gertz ME, Keles S, et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2015; 136(2): 402-412.

[15] Buchbinder D, Kirov I, Danielson J, et al. Compound heterozygous DOCK8 mutations in a patient with B lymphoblastic leukemia and EBV-associated diffuse large B cell lymphoma. J Clin Immunol. 2019; 39(6): 592-595.

[16] Kuşkonmaz B, Ayvaz D, Barış S, Ünal Ş, Tezcan İ, Uçkan D. Acute myeloid leukemia in a child with dedicator of cytokinesis 8 (DOCK8) deficiency. Pediatr Blood Cancer. 2017; 64(12): e26695.

[17] Su HC, Jing H, Angelus P, Freeman AF. Insights into immunity from clinical and basic science studies of DOCK8 immunodeficiency syndrome. Immunol Rev. 2019; 287(1): 9-19.

[18] Tangye SG, Pillay B, Randall KL, et al. Dedicator of cytokinesis 8-deficient CD4⁺ T cells are biased to a TH2 effector fate at the expense of TH1 and TH17 cells. J Allergy Clin Immunol. 2017; 139(3): 933-949.

[19] Schneider C, Shen C, Gopal AA, et al. Migration-induced cell shattering due to DOCK8 deficiency causes a type 2-biased helper T cell response. Nat Immunol. 2020; 21(12): 1528-1539.

[20] Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986; 136(7): 2348-2357.

[21] Keles S, Charbonnier LM, Kabaleeswaran V, et al. Dedicator of cytokinesis 8 regulates signal transducer and activator of transcription 3 activation and promotes TH17 cell differentiation. J Allergy Clin Immunol. 2016; 138(5): 1384-1394. e2.

[22] O’Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016; 16(9): 553-565.

[23] Almeida L, Dhillon-LaBrooy A, Carriche G, Berod L, Sparwasser T. CD4⁺ T-cell differentiation and function: Unifying glycolysis, fatty acid oxidation, polyamines NAD mitochondria. J Allergy Clin Immunol. 2021; 148(1): 16-32.

[24] Chapman NM, Chi H. Hallmarks of T-cell exit from quiescence. Cancer Immunol Res. 2018; 6(5): 502-508.

[25] Dang EV, Barbi J, Yang HY, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011; 146(5): 772-784.

[26] Singh AK, Eken A, Hagin D, et al. DOCK8 regulates fitness and function of regulatory T cells through modulation of IL-2 signaling. Insight. 2017; 2(19): e94275. 94275.

[27] Janssen E, Morbach H, Ullas S, et al. Dedicator of cytokinesis 8-deficient patients have a breakdown in peripheral B-cell tolerance and defective regulatory T cells. J Allergy Clin Immunol. 2014; 134(6): 1365-1374.

[28] Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. Nat Immunol. 2003; 4(4): 330-336.

[29] Li DY, Xiong XZ. ICOS+ Tregs: A functional subset of Tregs in immune diseases. Front Immunol. 2020; 11: 2104.

[30] Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. 2011; 12(4): 295-303.

[31] Shi LZ, Wang R, Huang G, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011; 208(7): 1367-1376.

[32] Wilson AS, Law HD, Knobbe-Thomsen CB, et al. Protection from EAE in DOCK8 mutant mice occurs despite increased Th17 cell frequencies in the periphery. Eur J Immunol. 2019; 49(5): 770-781.

[33] Aydin SE, Kilic SS, Aytekin C, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options—A review of 136 patients. J Clin Immunol. 2015; 35(2): 189-198.

[34] Luckheeram RV, Zhou R, Verma AD, Xia B. CD4⁺ T cells: Differentiation and functions. Clin Dev Immunol. 2012; 2012: 925135.

[35] Xie L, Fang J, Yu J, et al. The role of CD4+ T cells in tumor and chronic viral immune responses. MedComm. 2023; 4(5): e390.

[36] Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: From discovery to targeting. Trends Mol Med. 2016; 22(3): 230-241.

[37] Gharehzadehshirazi A, Amini A, Rezaei N. Hyper IgE syndromes: A clinical approach. Clin Immunol. 2022; 237: 108988.

[38] Li B, Yang K, Liang D, Jiang C, Ma Z. Discovery and development of selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors. Eur J Med Chem. 2021; 209: 112940.

[39] Zhang T, Guo Z, Huo X, et al. Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor. EBioMedicine. 2022; 77: 103872.

[40] Cai D, Wang J, Gao B, et al. RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. Nat Commun. 2019; 10(1): 4621.

[41] Wolf JJ, Studstill CJ, Hahm B. Emerging connections of S1P-metabolizing enzymes with host defense and immunity during virus infections. Viruses. 2019; 11(12): 1097.

[42] Ononye SN, Shi W, Wali VB, et al. Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets. Breast Cancer Res Treat. 2014; 148(3): 477-488.

[43] Voisinne G, Kersse K, Chaoui K, et al. Quantitative interactomics in primary T cells unveils TCR signal diversification extent and dynamics. Nat Immunol. 2019; 20(11): 1530-1541.

[44] Yang L, Jing Y, Kang D, et al. Ubiquitin-specific peptidase 18 regulates the differentiation and function of Treg cells. Genes Dis. 2021; 8(3): 344-352.

[45] Zhu Y, Gu H, Yang L, et al. Involvement of MST1/mTORC1/STAT1 activity in the regulation of B-cell receptor signalling by chemokine receptor 2. Clin Transl Med. 2022; 12(7): e887.

[46] Jiang P, Jing Y, Zhao S, et al. Expression of USP25 associates with fibrosis, inflammation and metabolism changes in IgG4-related disease. Nat Commun. 2024; 15(1): 2627.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.